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Metabotropic glutamate receptors as drug targets
for the treatment of absence epilepsy
Richard Teke Ngomba1 and Gilles van Luijtelaar2
Metabotropic glutamate (mGlu) receptors are expressed in key
regions of the cortex and the thalamus and are known to
regulate spike and wave discharges (SWDs), the electroclinical
hallmarks of absence seizures. Recent preclinical studies have
highlighted the therapeutic potential of selective group I and III
mGlu receptor subtype allosteric modulators, which can
suppress pathological SWDs. Of particular interest are positive
allosteric modulators (PAMs) for mGlu5 receptors, as they
currently show the most promise as novel anti-absence
epilepsy drugs. The rational design of novel selective positive
and negative allosteric mGlu modulators, especially for the
mGlu5 receptor, has been made possible following the recent
crystallographic structure determination of group I mGlu
receptors. Our current knowledge of the role of different mGlu
receptor subtypes in absence epilepsy is outlined in this article.
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Introduction
Absence epilepsy is non-convulsive and is characterized
by a sudden decrease in responsiveness, accompanied by
staring and the simultaneous appearance of highly ste-
reotypical bilateral symmetrical network activity in the
form of spike-and-wave discharges (SWDs) in the EEG.
The main anatomical structure where these SWDs are
generated is the extensive cortico–thalamo–cortical net-
work which includes the reticular thalamic nucleus (nRT)
[1,2,3,4]. The frontal cortex has been identified as the
major initiation site for SWDs in some patients [5],
although other cortical locations including the temporal,
occipital and parietal lobe can also be initiation sites [6].
In a widely used and validated genetic absence animal
model, the WAG/Rij strain of rat, the peri-oral region of
the somatosensory cortex (S1po) has been identified as
the SWD initiation site [5,7]. These WAG/Rij rats are an
inbred strain that shows an age-dependent increase in the
probability of developing spontaneous SWDs. Following
their development, SWDs increase in both frequency and
mean duration. SWDs occur mainly during passive wake-
fulness, in an otherwise motionless animal, not during
deep slow wave sleep. During SWDs, animals do not
make overt behavioural responses to obtain food pellets,
as they would do normally suggesting that responsiveness
is reduced.
Many classical and newer antiepileptic drugs have been
tested in this and in a similar absence model, the GAERS
(Genetic absence epilepsy rats from Strasbourg). Based
on the outcomes of such experiments, it has been con-
cluded that these animal models provide a good predic-
tion of the efficacy of drugs and the possible off-target
effects that will be observed in humans with absence
seizures [3].
The glutamatergic and GABAergic systems are involved
in controlling excitation and inhibition respectively, in
the cortex and thalamus. Aside from the highly excitable
site in the cortex that initiates SWDs in WAG/Rij rats and
in GAERS, increased thalamic tonic GABAergic inhibi-
tion has also been demonstrated in some genetic absence
epilepsy models [7,8]. The fact that metabotropic glu-
tamate (mGlu) receptors are expressed in different
regional circuit cell types within cortico-thalamo-cortical
networks, and that they modulate synaptic transmission
[9,10,11] (see also Figure 1), suggest a potential role for
mGlu receptors in regulating SWDs.
The mGlu receptors are classified into three main groups
(I, II and III), and pre-clinical studies to date have shown
that ligands for the different receptor subtypes in each
group have anti-absence properties [12,13–15,16,17–
19].
Furthermore, interest in identifying new mGlu receptor
ligands with anti-absence properties has been encouraged
by the discovery of distinct allosteric binding sites in the
crystallographic structure of transmembrane domains in
group I mGlu receptors (mGlu1 and mGlu5 receptors),
permitting a rational design of specific compounds
[20,21]. Here, we focus on the role of mGlu receptors
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and their allosteric modulators as studied in the WAG/Rij
rat model of absence epilepsy [3].
Localization and modulation of mGlu
receptors in the cortico–thalamo–cortical
circuitry
The classification of mGlu receptors into groups is based
on their pharmacological properties and amino acid
sequence homology profile [12,22,23]. These receptors
are coupled to different G proteins and they modulate
slow postsynaptic neuronal responses, either through the
presynaptic or postsynaptic machinery or through modu-
lating astrocytes function [9,10,11,12,24] (see also
Figure 1).
Group I mGlu receptors
mGlu1 and mGlu5 receptor subtypes are members of
group I and they are coupled to Gq/G11 proteins, which
upon activation trigger polyphosphoinositide hydrolysis
leading to the production of inositol-1,4,5-trisphosphate
and diacylglycerol. These receptors are also able to regu-
late the activity of different types of Ca2+ and K+ channels
44 Neurosciences
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Diagram showing synaptic localization of mGlu receptor subtypes in the modulation of absence seizures. In red, dendritic spine from the
pyramidal cell (e.g. layer IV), cortico-thalamic (CT) glutamatergic projection into the ventrobasal thalamus with collateral onto the reticular thalamic
nucleus (nRT). Glutamatergic thalamic relay neuron (TC) sends projection (in orange) to the deep layers of the cortex (e.g. layer VI) and collateral
onto the nRT. GABAergic nRT neuron in green, sending projection to the VB and collateral back onto the nRT. The synapses are mostly
surrounded by astrocytic processes (in purple) expressing distinct mGlu receptor subtypes (principally mGlu3 and mGlu5) as indicated by the
different colours. The sensory afferents at the thalamus are depicted as a large red arrow. mGlu1 and mGlu5 receptors (also present on
astrocytes) are located perisynaptically at excitatory synapses. Group II receptors (mGlu2 and 3) are present in both cortical and thalamic synaptic
terminals. mGlu3 receptors are expressed in astrocytes, and the activity of mGlu2 has recently been identified on astrocytes by a combination of
electrophysiological and pharmacological methods. Subtypes of mGlu4, 7 and 8 are usually localized presynaptically at active regions.
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[22,25,26] (see also Table 1). Data from molecular studies
show that they are localized on postsynaptic dendrites of
thalamic neurons and on GABAergic interneurons in the
cortex [27–30]. Glial cells expressing mGlu5 receptors
may also modulate synapses within the thalamus, partic-
ularly on inputs to the somatosensory ventrobasal (VB)
thalamus [31] (see also Figure 1).
Group I mGlu receptors are the most extensively studied
group in the WAG/Rij rat model [12,13–15,16]: the
expression of both receptor subtypes (mGlu1 and mGlu5)
have been shown to be reduced in the thalamus as
compared to non-epileptic ACI control rats [13,14]. Simi-
lar results have been observed for mGlu1 expression in
the laterodorsal thalamus in the same model [32]. Inter-
estingly, mGlu5 receptor expression was up-regulated in
the motor cortex and in the S1po region, again in com-
parison with age-matched ACI rats, without any change in
mGlu5 receptor function. Overall, both receptors show
reduced expression and activity in the cortico-thalamo-
cortical network in the WAG/Rij rat [13,14,32].
Electroencephalographic (EEG) studies carried out fol-
lowing systemic treatment with the specific mGlu1 recep-
tor positive allosteric modulator (PAM) RO0711401
showed a long-lasting (6 hours) dose-related reduction
in frequency and duration of SWDs (the latter only
occurring only after the highest dose). As expected,
treatment with the mGlu1 negative allosteric modulator
(NAM) JNJ16259685 increased the incidence of SWDs
[13] (see also Table 1). The mGlu5 receptor PAM
VU0360172 reduced the number of SWDs in a dose-
dependent manner, without any behavioural changes,
such as an increase or decrease in locomotor activity in
the home cage. The reduction of SWDs was antagonized
by the mGlu5 receptor NAM, MTEP. MTEP itself was
without any effect on SWDs [13] (see also Table 1). The
lack of behavioural effects is important since clinically
useful anti-epileptic drugs should lack sedative or hyp-
notic effects. Intriguingly, MPEP significantly reduced
the occurrence of SWDs in the lethargic mouse (lh/lh)
model [33–35], a different genetic absence model, in
which animals show an ataxic gait in addition to SWDs.
Moreover, the mGlu1 receptor orthosteric antagonists
AIDA and LY367385 reduced SWDs in the same model
[34]. These results are in contrast with those obtained in
WAG/Rij rats. It is not clear whether these differences
could be due to the different species used or to differ-
ences in ligand-site activity on receptor subtypes.
Considering that absence epilepsy is a chronic disease
requiring long-term treatment, the effects of chronic
administration of both selective group I receptor subtype
PAMs were tested to see whether tolerance developed to
the suppressing effects on SWDs. WAG/Rij rats were
treated with comparable doses of each compound
(RO0711401 and VU0360172) for 10 days twice daily.
The rats developed complete tolerance to RO0711401
after 2 days, while VU0360172 maintained its anti-SWD
effects throughout this period and even after 48 hours
from ceasing treatment [15] (see also Table 1). The
mechanism for this tolerance remains unclear, but it limits
the clinical usefulness of RO0711401.
Further studies have been carried out to determine which
regions within the cortex or the thalamus were responsi-
ble for the effects observed following systemic injection
of the mGlu1 or mGlu5 receptor PAMs. When either
RO0711401 or VU0360172 were individually adminis-
tered locally into the cortex or the thalamus, both pro-
portionally reduced SWDs. However, when introduced
into the thalamus, VU0360172 had a more pronounced
efficacy than RO0711401 [16].
How do these PAMs reduce SWDs? Both mGlu1 and
mGlu5 receptors are coupled to second messenger effec-
tors, including PLC-beta 4; these may negatively regulate
T-type calcium channels in the cortex and thalamus,
reducing SWDs [36–39]. Of note, mutation of PLC-beta
4 is known to influence pathological cortico–thalamo–
cortical rhythms associated with T-type channels [40].
As previously stated, in physiological conditions glutamate
and GABA are in a critical balance within the cortico–
thalamo–cortical network [1,12,16]. Coenen and colla-
borators have shown that systemic injection of tiagabine a
GABA re-uptake inhibitor with high affinity at the GABA
transporter (GAT-1) — upset the balance, leading to
increased SWD frequency and duration in WAG/Rij rats
[41]. When tiagabine was administered intra-cortically at
the focal region, it reduced the number of SWDs, similarly
to the effect produced by local infusion of VU0360172 [16].
Intra-cortical injection of VU0360172 in combination with
tiagabine produced a slight prolongation of the SWD
suppressive effect, suggesting that the modes of action of
VU0360172 and tiagabine may be similar [16]. Opposite
results were obtained when tiagabine was infused in the
thalamus: it enhanced SWDs, most likely by increasing
GABA levels perisynaptically at thalamic relay cells. Inter-
estingly, VU0360172 lost its anti-absence action when it was
infused in the thalamus in combination with tiagabine [16].
Regarding VU0360172, the group I mGlu5 receptor PAM,
it produced neither tolerance nor overt effects on behav-
iour but had good efficacy in the cortex and thalamus.
Interestingly, one of the drugs of choice in the treatment
of absence epilepsy, ethosuximide, is also highly effective
in the cortex, but less so in the thalamus [42,63]. This
demonstrates the importance of targeting mGlu5 recep-
tors for the development of novel anti-absence drugs.
Group II mGlu receptors
Group II (mGlu2 and mGlu3) receptors are coupled to Gi/
Go proteins, which inhibit the activity of adenyl cyclase
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Table 1
A summary of mGlu receptor subtypes, transduction mechanisms and site of action of specific subtype receptor ligands and their effect on models of absence epilepsy.
Group I Group II Group III
Receptor subtypes and
ligand sites of action
Expression and canonic
transduction Pathways
 Group I mGlu receptors are predominantly expressed post-
synaptically and mGlu5 are also on astrocytes
 Group II mGlu receptors are both expressed
pre and post-synaptically. mGlu3 are on
astrocytes and recently mGlu2 astrocytic
activity has been identified in the thalamus
 Group III mGlu receptors are predominantly
expressed presynaptically
 Associated with Gq/11 class G proteins
 PLC stimulation
 Stimulation of adenylyl cyclase
 MAP kinase phosphorylation
 Associated with Gi/o class G proteins
 Inhibition of adenylyl cyclase
 Activation of K+ channels
 Inhibition of Ca2+ channels
 Associated with Gi/o class G proteins
 Inhibition of adenylyl cyclase
 Activation of K+ channels
 Inhibition of Ca2+ channels
Ligand effects related to
absence epilepsy
 RO0711401 reduces SWDs (WAG/Rij rats) and JNJ16259685
increases SWDs (WAG/Rij rats) [13]
 Orthosteric antagonists LY367385 and AIDA reduces SWDs in
Ih/Ih mice [33–35]
 VU0360172 reduces SWDs in WAG/Rij rats: MTEP antagonizes
the effect of VU0360172 in WAG/Rij rats [14].
 MPEP mGlu5 NAM with an mGlu4 NAM component reduces
SWDs in Ih/Ih mice [33]
 Development of tolerance: VU0360172 (NON after 10 days),
while RO0711401 did develop after 2 days [15]
 Local infusion of either RO0711401 or VU0360172 suppressed
SWDs independently both in the cortex and thalamus [16]
 LY341495 an orthosteric antagonist reduces
SWDs in WAG/Rij rats [17]
 LY379268 an orthosteric agonist increases
SWDs in WAG/Rij rats [17]. LY389795 and
LY379268 both reduces SWDs in Ih/Ih mice [45]
 PHCCC enhances SWDs in WAG/Rij rats [9]
 ADX71743 produces lethargic effects similar to
SWDs in WT mice [19]. Decoupling if PICK1 from
mGlu7 causes SWDs [56]
OrthoAgo = Orthosteric agonist
OrthoAnt = Orthosteric antagonist
PAM = positive allosteric modulator
NAM = negative allosteric modulator
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and voltage-sensitive Ca2+ channels (VSCCs) [22,26].
Molecular analysis shows that mGlu3 receptors have a
higher expression on GABAergic terminals of the nRT
than at glutamatergic synapses. These receptors are also
present on axons of cortical layer VI [43]. mGlu3 receptors
are expressed by glial cells, and mGlu2 receptor activity
has been identified in astrocytes in the ventrobasal tha-
lamic nuclei [11,12,17,28,43,44] (see also Figure 1).
In symptomatic WAG/Rij rats, mGlu2/3 receptor expres-
sion in the S1po area is altered as compared with age-
matched controls [17]. Only a few pharmacological stud-
ies have been carried out with orthosteric ligands for these
receptors, one in WAG/Rij rats [17] and one in 1h/1h mice
[45]. In WAG/Rij rats, blockade of the mGlu2/3 receptor
with the antagonist LY341495 reduced the occurrence of
SWDs in a dose-dependent manner, while activation of
these receptors had opposite effects [17]. Intriguingly,
activation of the mGlu2/3 receptor in 1h/1h mice
decreased SWDs activity [45]. It is not known whether
these contrasting results are due to (mGlu2 or mGlu3)
receptor/ligand selectivity, specificity or model/species
differences. The development of novel specific ligands
for mGlu2 and mGlu3 receptors combined with genetic
manipulation of these receptors might be relevant to
unravelling the specific role of each subtype.
Group III mGlu receptors
Group III comprises mGlu4, mGlu6, mGlu7 and mGlu8
receptors, which are also coupled to Gi/Go proteins,
similar to group II receptors. All except mGlu6 are
expressed in the cortico-thalamo-cortical network. mGlu4
receptors are found on glutamatergic terminals in the
nRT and in the VB, while mGlu7 and mGlu8 are present
also on nRT neurons [9,12,18,46–50].
Group III mGlu receptors seem to be important in the
mechanisms underlying the initiation of absence seizures.
Different studies link the human mGlu4 receptor gene to
genetic/idiopathic generalised epilepsies [51–53]. mGlu4
receptor expression is increased in the nRT of symptom-
atic WAG/Rij rats as compared with asymptomatic control
rats; pharmacological enhancement of the activation of
this receptor with the PAM PHCCC increased SWDs [9].
The other group III receptors (namely, mGlu7 and
mGlu8) are implicated in the modulation of neuronal
plasticity, learning, and memory [54,55], and are also
involved in seizures and epilepsy [56]. mGlu7 knockout
mice show increased susceptibility to chemically induced
seizures [54]. The lack of specific subtype ligands for
group III mGlu receptors has limited the studies of their
individual roles in absence seizures.
The mGlu7 receptor has a very low affinity for glutamate,
and this allows selective recruitment of the receptor
during high levels of synaptic activity [57]. Conversely,
prolonged agonist activation of the mGlu7 receptor can
also activate a phospholipase C-mediated signalling path-
way that enhances glutamate release [58].
Nevertheless, knockout mice in which PDZ-interaction
with protein-interaction-C-kinase-1 (PICK-1) signalling
decoupled from the C-terminus of the mGlu7 receptor
develop spontaneous absence-like epilepsy [56]. In addi-
tion, a study by Kyuyong and Huguenard has demon-
strated that mGlu7 receptors are functionally present as
autoreceptors on inhibitory synapses between nRT and
thalamocortical neurons [18] (see also Table 1).
A recent study demonstrated that mGlu7 receptors are
found on synapses projecting onto the nRT, and from the
nRT onto the VB [19] (see also Figure 1). Blockade of
mGlu7 receptor activity with the specific mGlu7 receptor
NAM ADX71743 induced a lethargic condition similar to
absence seizures with spindle and/or SWDs. The authors
showed that the mGlu7 receptor regulates tonic modula-
tion, particularly between GABAergic and glutamatergic
synapses within the cortico-thalamo-cortical network
[19].
In terms of the group III receptors, the properties and
location of the mGlu7 receptor make it an attractive target
in that mGlu7 receptor ligands might be beneficial for the
development of anti-absence epilepsy drugs.
Conclusion
Targeting subtype-selective metabotropic glutamate
receptor is a potentially novel method for treating
absence seizures given that many of these receptors are
expressed in the thalamo–cortico–thalamic circuit and
studies with agents that modulate receptor activity show
promise in reducing SWD occurrence in animal models.
The challenge will be to provide an alternative therapy to
current medication for the 40% of absence epilepsy
patients who are resistant to current drugs [59]. Hypo-
thetically, mGlu PAMs could be developed for sufferers
of absence seizures refractory to conventional medica-
tions. Indeed, ligands for mGlu receptors have been
under phase I and II clinical investigation for the treat-
ment of CNS disorders [26,60]. As an ultimate goal, the
further design of subtype mGlu receptor PAMs with
biased allosteric modulatory properties is relevant to
delivering in vivo efficacy and the elimination of adverse
effects.
We propose that designing mGlu receptor ligands with a
modulatory effect on voltage-gated channels (primarily
Cav3.1, the major T-channel in TC neurons) affecting
neuronal electrical properties during seizures would lead
to effective anti-absence therapy with reduced side
effects associated with non-specific anti-absence medica-
tion, such as ethosuximide, which acts on Na+ channels as
well as T-channels [61–63].
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